<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="14973">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01929408</url>
  </required_header>
  <id_info>
    <org_study_id>2368.00</org_study_id>
    <secondary_id>RSG-13-084-01-CPHPS</secondary_id>
    <nct_id>NCT01929408</nct_id>
  </id_info>
  <brief_title>Feasibility and Outcomes of Allogeneic HCT Compared to Chemotherapy in Older AML Patients</brief_title>
  <official_title>Feasibility and Outcomes of Allogeneic Hematopoietic Cell Transplantation (HCT) Compared to Conventional Therapy for Older and Medically Infirm Patients Diagnosed With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes: A Prospective Observational Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fred Hutchinson Cancer Research Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Patient Centered Outcome Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>American Cancer Society, Inc.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Fred Hutchinson Cancer Research Center</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare treatment methods and outcomes of patients diagnosed
      with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective multicenter observational study in a Consortium of collaborating
      institutions investigating how often older and medically infirm patients who are diagnosed
      with Acute Myeloid Leukemia (AML) or high-risk myelodysplastic syndromes (MDS) and treated
      with induction chemotherapy undergo allogeneic HCT. Investigators will look at the rate of
      undergoing allogeneic HCT among older and medically infirm AML and high-risk MDS patients
      compared to younger and relatively healthier patients. Investigators will also compare the
      characteristics and outcomes of patients who did versus did not proceed to allogeneic HCT. A
      number of outcomes will be assessed including mortality, morbidity, and quality of life
      (QOL). Baseline information will be collected on different domains of QOL, geriatric
      assessment, health status measures, AML features, and socioeconomic status. Information will
      help physicians and patients to decide on best treatment choices for AML and high-risk MDS
      in older and medically infirm patients.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Non-Relapse Mortality (NRM)</measure>
    <time_frame>2 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Investigators will assess non-relapse mortality (NRM) of patients enrolled in the study.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>2 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Investigators will assess Overall Survival (OS) of patients enrolled in the study.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Disease Free Survival (DFS)</measure>
    <time_frame>2 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Investigators will assess Disease Free Survival (DFS) of patients enrolled in the study.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>2 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>QOL and symptoms will be assessed longitudinally using 7 measures covering physical, functional, social/family, emotional well-being mobility, self-care, usual activities, pain/discomfort, anxiety/depression, and social activities.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Acute Myeloid Leukemia (AML)</condition>
  <condition>Myelodysplastic Syndrome (MDS)</condition>
  <eligibility>
    <study_pop>
      <textblock>
        The study population will include non-M3 AML and high-risk MDS patients considered for
        induction chemotherapy at FHCRC and the Seattle Cancer Care Alliance Network and five
        other Core institutions (Stanford School of Medicine, Cleveland Clinic, Northwestern
        University, Massachusetts General Hospital, and University of Utah) in addition to an
        unidentified number of affiliate sites. We anticipate enrollment of a total sample of 1000
        patients.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with new diagnoses of non-M3 AML or high-risk MDS who present for AML-like
             treatment that could plausibly produce a complete remission (CR); for example
             intensive induction chemotherapy, low dose single agent chemotherapy,
             hypo-methylation agent, or a similar therapy

          -  Explicitly intend to establish follow-up care at one of the collaborating
             institutions.

          -  Patients of ≥18 years of age and are being treated by the adult AML service.

          -  Able to read and speak English.

          -  Willing and able to provide informed consent.

        Exclusion Criteria:

          -  Patients of ≤17 years of age or who are ≥18 and receive treatment under the pediatric
             AML service.

          -  Patients older than 80 years

          -  Patients with &lt;6 months projected survival due to active second malignancy or other
             medical problem.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mohamed Sorror, MD, MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistant Member, FHCRC; Assistant Professor of Medicine, UW</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nazila Dabestani, BA</last_name>
    <phone>206-667-6122</phone>
    <email>ndabesta@fhcrc.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Shylo Wardyn, MS</last_name>
    <phone>206-667-7263</phone>
    <email>swardyn@fhcrc.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Stanford Cancer Institute</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jack Taw, CRC</last_name>
      <phone>650-723-2781</phone>
      <email>jtaw@stanford.edu</email>
    </contact>
    <investigator>
      <last_name>Bruno Medeiros, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwestern Memorial Hospital</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Nam, BA</last_name>
      <phone>312-695-1659</phone>
      <email>jennifer-nam@northwestern.edu</email>
    </contact>
    <investigator>
      <last_name>Jessica Altman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Andrew Brunner, MD</last_name>
      <phone>617-726-2865</phone>
      <email>andrew_brunner@dfci.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Amir Fathi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Andrew Brunner, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cassandra Fincher</last_name>
      <phone>216-445-3795</phone>
      <email>finchec@ccf.org</email>
    </contact>
    <investigator>
      <last_name>Aaron Gerds, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Karen Pena, Bachelors</last_name>
      <phone>801-213-4233</phone>
      <email>karen.pena@hci.utah.edu</email>
    </contact>
    <investigator>
      <last_name>Paul Shami, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>FHCRC</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nazila Dabestani, BA</last_name>
      <phone>206-667-6122</phone>
      <email>ndabesta@fhcrc.org</email>
    </contact>
    <contact_backup>
      <last_name>Shylo Wardyn, MS</last_name>
      <phone>206-667-7263</phone>
      <email>swardyn@fhcrc.org</email>
    </contact_backup>
    <investigator>
      <last_name>Mohamed Sorror, MD, MSc</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>SCCA Network Clinics</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>SCCA Network Research Office General Line</last_name>
      <phone>206-288-7232</phone>
    </contact>
    <investigator>
      <last_name>Jack Hensold, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Thomas Rado, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Eric Chen, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Troy Wadsworth, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Thomas Kummet, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jeanne Anderson, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Aimee Kohn, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kiarash Kojouri, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mitchell Garrison, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 19, 2014</lastchanged_date>
  <firstreceived_date>August 14, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
